Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
about
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Upfront lower dose lenalidomid ...... of the phase II RevLite study.
@en
type
label
Upfront lower dose lenalidomid ...... of the phase II RevLite study.
@en
prefLabel
Upfront lower dose lenalidomid ...... of the phase II RevLite study.
@en
P2093
P2860
P50
P356
P1476
Upfront lower dose lenalidomid ...... of the phase II RevLite study.
@en
P2093
Annette Neylon
Arlene Swern
Bart Baker
Cecily Forsyth
Craig Underhill
Gillian Corbett
H Miles Prince
Hang Quach
Hilary Blacklock
P2860
P304
P356
10.1111/BJH.14562
P407
P577
2017-02-15T00:00:00Z